FI956341A0 - Metyylifosfonihappoesteri, menetelmä sen valmistamiseksi ja sen käyttö - Google Patents
Metyylifosfonihappoesteri, menetelmä sen valmistamiseksi ja sen käyttöInfo
- Publication number
- FI956341A0 FI956341A0 FI956341A FI956341A FI956341A0 FI 956341 A0 FI956341 A0 FI 956341A0 FI 956341 A FI956341 A FI 956341A FI 956341 A FI956341 A FI 956341A FI 956341 A0 FI956341 A0 FI 956341A0
- Authority
- FI
- Finland
- Prior art keywords
- pct
- making
- acid ester
- methylphosphonic acid
- date jan
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- -1 Methylphosphonic acid ester Chemical class 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4321946 | 1993-07-01 | ||
DE4321946A DE4321946A1 (de) | 1993-07-01 | 1993-07-01 | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
PCT/EP1994/002121 WO1995001363A1 (de) | 1993-07-01 | 1994-06-29 | Methylphosphonsäureester, verfahren zu deren herstellung und deren verwendung |
EP9402121 | 1994-06-29 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI956341A0 true FI956341A0 (fi) | 1995-12-29 |
FI956341A FI956341A (fi) | 1996-02-19 |
FI115399B FI115399B (fi) | 2005-04-29 |
Family
ID=6491730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI956341A FI115399B (fi) | 1993-07-01 | 1995-12-29 | Menetelmä terapeuttisesti käyttökelpoisten metyylifosfonihappoestereiden valmistamiseksi |
Country Status (13)
Country | Link |
---|---|
US (1) | US6028182A (fi) |
EP (1) | EP0707591B1 (fi) |
JP (1) | JP3831407B2 (fi) |
AT (1) | ATE206130T1 (fi) |
AU (1) | AU698928B2 (fi) |
CA (1) | CA2165971C (fi) |
DE (2) | DE4321946A1 (fi) |
DK (1) | DK0707591T3 (fi) |
ES (1) | ES2165391T3 (fi) |
FI (1) | FI115399B (fi) |
NO (1) | NO319860B1 (fi) |
PT (1) | PT707591E (fi) |
WO (1) | WO1995001363A1 (fi) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
DE4331670A1 (de) * | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
DE4338704A1 (de) | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilisierte Oligonucleotide und deren Verwendung |
DE19502912A1 (de) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
ES2165446T3 (es) * | 1995-03-13 | 2002-03-16 | Aventis Pharma Gmbh | Fosfonomonoester-acidos nucleicos, procedimiento para su preparacion y su utilizacion. |
US5821354A (en) * | 1996-11-26 | 1998-10-13 | Angiogene Inc. | Radiolabeled DNA oligonucleotide and method of preparation |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
ATE342911T1 (de) * | 1996-12-24 | 2006-11-15 | Sirna Therapeutics Inc | Synthese von nukleosiden und polynukleotiden |
WO2000048630A1 (en) | 1999-02-17 | 2000-08-24 | Csl Limited | Immunogenic complexes and methods relating thereto |
DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
US20020119178A1 (en) * | 2001-02-23 | 2002-08-29 | Luc Levesque | Drug eluting device for treating vascular diseases |
GB0110732D0 (en) * | 2001-05-02 | 2001-06-27 | Psl Technology Ltd | Apparatus and method |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
ATE544466T1 (de) | 2002-10-29 | 2012-02-15 | Coley Pharm Group Inc | Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion |
WO2005097993A2 (en) | 2004-02-19 | 2005-10-20 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
NZ553244A (en) | 2004-07-18 | 2009-10-30 | Csl Ltd | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
ES2553284T5 (es) | 2006-02-15 | 2021-08-31 | Rechtsanwalt Thomas Beck | Composiciones y procedimientos para formulaciones de oligonucleótidos |
NZ575437A (en) | 2006-09-27 | 2012-02-24 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity |
KR20100010509A (ko) * | 2007-05-17 | 2010-02-01 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 면역자극 효과를 갖는 a 클래스 올리고뉴클레오타이드 |
KR20100068422A (ko) | 2007-10-09 | 2010-06-23 | 콜리 파마슈티칼 게엠베하 | 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체 |
EP2306986B1 (en) | 2008-06-26 | 2018-03-21 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
EP2376108B1 (en) | 2008-12-09 | 2017-02-22 | Pfizer Vaccines LLC | IgE CH3 PEPTIDE VACCINE |
PE20110998A1 (es) | 2008-12-09 | 2012-02-10 | Coley Pharm Group Inc | Oligonucleotidos inmunoestimuladores |
PE20120817A1 (es) | 2009-07-30 | 2012-07-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos |
US10456463B2 (en) | 2010-05-28 | 2019-10-29 | Zoetis Belgium S.A | Vaccines comprising cholesterol and CpG as sole adjuvant-carrier molecules |
CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
MX359257B (es) | 2012-05-04 | 2018-09-19 | Pfizer | Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna. |
WO2016109310A1 (en) | 2014-12-31 | 2016-07-07 | Checkmate Pharmaceuticals, Llc | Combination tumor immunotherapy |
JP7511478B2 (ja) | 2018-04-09 | 2024-07-05 | チェックメイト ファーマシューティカルズ | ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化 |
WO2024127215A2 (en) | 2022-12-13 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010140A1 (en) * | 1991-11-21 | 1993-05-27 | Pharmagenics, Inc. | Oligonucleotides having modified anionic moieties |
-
1993
- 1993-07-01 DE DE4321946A patent/DE4321946A1/de not_active Withdrawn
-
1994
- 1994-06-29 ES ES94919670T patent/ES2165391T3/es not_active Expired - Lifetime
- 1994-06-29 WO PCT/EP1994/002121 patent/WO1995001363A1/de active IP Right Grant
- 1994-06-29 DE DE59409880T patent/DE59409880D1/de not_active Expired - Fee Related
- 1994-06-29 CA CA002165971A patent/CA2165971C/en not_active Expired - Fee Related
- 1994-06-29 AU AU70735/94A patent/AU698928B2/en not_active Ceased
- 1994-06-29 JP JP50326995A patent/JP3831407B2/ja not_active Expired - Fee Related
- 1994-06-29 US US08/578,686 patent/US6028182A/en not_active Expired - Fee Related
- 1994-06-29 DK DK94919670T patent/DK0707591T3/da active
- 1994-06-29 EP EP94919670A patent/EP0707591B1/de not_active Expired - Lifetime
- 1994-06-29 PT PT94919670T patent/PT707591E/pt unknown
- 1994-06-29 AT AT94919670T patent/ATE206130T1/de not_active IP Right Cessation
-
1995
- 1995-12-29 NO NO19955352A patent/NO319860B1/no unknown
- 1995-12-29 FI FI956341A patent/FI115399B/fi active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DE4321946A1 (de) | 1995-01-12 |
NO955352L (no) | 1996-02-14 |
JPH08512039A (ja) | 1996-12-17 |
JP3831407B2 (ja) | 2006-10-11 |
ES2165391T3 (es) | 2002-03-16 |
US6028182A (en) | 2000-02-22 |
NO955352D0 (no) | 1995-12-29 |
WO1995001363A1 (de) | 1995-01-12 |
EP0707591A1 (de) | 1996-04-24 |
CA2165971A1 (en) | 1995-01-12 |
PT707591E (pt) | 2002-03-28 |
EP0707591B1 (de) | 2001-09-26 |
FI956341A (fi) | 1996-02-19 |
CA2165971C (en) | 2006-05-30 |
FI115399B (fi) | 2005-04-29 |
ATE206130T1 (de) | 2001-10-15 |
DK0707591T3 (da) | 2002-01-21 |
NO319860B1 (no) | 2005-09-26 |
AU698928B2 (en) | 1998-11-12 |
AU7073594A (en) | 1995-01-24 |
DE59409880D1 (de) | 2001-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI956341A0 (fi) | Metyylifosfonihappoesteri, menetelmä sen valmistamiseksi ja sen käyttö | |
AU4115396A (en) | 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these | |
FI952607A (fi) | Farmakologisesti aktiiviset pyridiinijohdannaiset ja menetelmät niiden valmistamiseksi | |
FI113644B (fi) | Menetelmä terapeuttisesti aktiivisten N-substituoitujen 3- atsabisykloalkaanijohdannaisten valmistamiseksi | |
IL116385A (en) | Sulphonamides their manufacture and pharmaceutical compositions containing them | |
EP0980866A3 (en) | Phenyl heterocycles as cyclooxygenase-2 inhibitors | |
HUT77925A (hu) | Dihidrobenzofuránok, azokat tartalmazó gyógyászati készítmények és eljárás előállításukra | |
NZ330216A (en) | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and use in treatment of atherosclerosis | |
EP0842661A3 (en) | Atherosclerosis treatment | |
DE59309649D1 (de) | Substituierte Cyclohexan-Derivate zur Behandlung von Krankheiten | |
CA2094806A1 (en) | Aminosulfonyl urea acat inhibitors | |
FI960149A0 (fi) | Kumariinien ja karbostyriilien käyttö PLA2:n estäjinä, uusia kumariineja ja karbostyriilejä, menetelmä niiden valmistamiseksi ja lääkkeitä | |
PL314840A1 (en) | N-substituted derivatives of azabicycloheptane | |
TW261614B (fi) | ||
MX9708735A (es) | Benzotiazoles y benzoxazoles, composiciones farmaceuticas que contienen estos compuestos y su uso y proceso para prepararlos. | |
DE69917668D1 (de) | Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung | |
AU3473595A (en) | Novel phosphane oxides, method of preparing them and drugs containing these compounds | |
PL309339A1 (en) | Novel triazoquinazolines, methods of obtaining them and their application | |
EP0036650A3 (de) | Cephalosporinderivate, entsprechende Präparate, die Verwendung dieser Produkte bei der Behandlung von Krankheiten, die Herstellung der Wirkstoffe sowie dabei anfallende Zwischenprodukte | |
IT1244649B (it) | Procedimento per il trattamento di substrati com composti aromatici contenenti gruppi solfo, composizioni contenenti tali composti e loro preparazione | |
HUP9903369A2 (hu) | 8(9)-Dehidroösztradiol-származékok | |
JO1697B1 (en) | Pyridine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 115399 Country of ref document: FI |